New Publications Advance Understanding of Paratonia and Support More Compassionate CareTORONTO, June 8, 2026 /PRNewswire/ - Baycrest researchers and clinicians have contributed to newly...
NEWARK, Del., June 8, 2026 /PRNewswire/ -- The global High-performance Fiber Market is entering a new phase of strategic expansion, supported by rising aerospace production,...
NEWARK, Del., June 8, 2026 /PRNewswire/ -- The global High-performance Fiber Market is entering a new phase of strategic expansion, supported by rising aerospace production,...
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area...
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in...
SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical...
Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...
Copenhagen, Denmark, 7 June2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.
SHANGHAI, June 5, 2026 /PRNewswire/ -- Recently, the highly anticipated 34th China International Bicycle Exhibition (CHINA CYCLE) concluded successfully at the Shanghai New International...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.
NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....